132 related articles for article (PubMed ID: 19289354)
1. New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin.
Hussar DA
J Am Pharm Assoc (2003); 2009; 49(2):347-50. PubMed ID: 19289354
[No Abstract] [Full Text] [Related]
2. Fesoterodine (toviaz) for overactive bladder.
Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719
[No Abstract] [Full Text] [Related]
3. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Michel MC
Expert Opin Pharmacother; 2008 Jul; 9(10):1787-96. PubMed ID: 18570610
[TBL] [Abstract][Full Text] [Related]
4. Treatment of men with lower urinary tract symptoms and overactive bladder.
Bell WA; Amarshi N
JAMA; 2007 Mar; 297(11):1192; author reply 1193. PubMed ID: 17374810
[No Abstract] [Full Text] [Related]
5. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
Kraus SR; Ruiz-Cerdá JL; Martire D; Wang JT; Wagg AS
Urology; 2010 Dec; 76(6):1350-7. PubMed ID: 20974482
[TBL] [Abstract][Full Text] [Related]
7. Review of fesoterodine.
Vella M; Cardozo L
Expert Opin Drug Saf; 2011 Sep; 10(5):805-8. PubMed ID: 21639817
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Speakman MJ
Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
[No Abstract] [Full Text] [Related]
9. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Dmochowski R
Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
[No Abstract] [Full Text] [Related]
10. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
Lepor H; Hill LA
Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
[TBL] [Abstract][Full Text] [Related]
11. New drug information: Toviaz.
Physician Assistants' Prescribing Reference
JAAPA; 2009 Jun; 22(6):12. PubMed ID: 19601442
[No Abstract] [Full Text] [Related]
12. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
13. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.
Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Choo MS
BJU Int; 2011 Feb; 107(4):603-11. PubMed ID: 20860648
[TBL] [Abstract][Full Text] [Related]
14. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
15. Toviaz approved for overactive bladder.
Traynor K
Am J Health Syst Pharm; 2008 Dec; 65(23):2184. PubMed ID: 19020177
[No Abstract] [Full Text] [Related]
16. Silodosin for benign prostatic hyperplasia.
Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
Chapple CR; Herschorn S; Abrams P; Wang JT; Brodsky M; Guan Z
BJU Int; 2010 Nov; 106(9):1332-8. PubMed ID: 20497416
[TBL] [Abstract][Full Text] [Related]
18. Fesoterodine for the treatment of overactive bladder.
Belavic JM
Nurse Pract; 2009 Aug; 34(8):14-5. PubMed ID: 19638887
[No Abstract] [Full Text] [Related]
19. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
[TBL] [Abstract][Full Text] [Related]
20. Fesoterodine.
McKeage K; Keating GM
Drugs; 2009; 69(6):731-8. PubMed ID: 19405552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
